Recro Pharma (REPH) Now Covered by Analysts at CIBC

CIBC began coverage on shares of Recro Pharma (NASDAQ:REPH) in a report released on Wednesday. The brokerage issued an outperform rating and a $19.00 target price on the specialty pharmaceutical company’s stock.

Other analysts have also issued reports about the company. Zacks Investment Research raised Recro Pharma from a hold rating to a buy rating and set a $9.75 price objective for the company in a report on Wednesday, November 15th. Piper Jaffray Companies reissued a buy rating and issued a $11.00 price objective on shares of Recro Pharma in a report on Friday, October 27th. UBS Group initiated coverage on Recro Pharma in a report on Tuesday. They issued an outperform rating for the company. Finally, Oppenheimer initiated coverage on Recro Pharma in a report on Tuesday. They issued an outperform rating and a $19.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $13.75.

Shares of Recro Pharma (NASDAQ:REPH) opened at $8.50 on Wednesday. The company has a quick ratio of 1.35, a current ratio of 1.59 and a debt-to-equity ratio of 0.50. Recro Pharma has a fifty-two week low of $5.81 and a fifty-two week high of $10.59.

In other news, major shareholder Scp Vitalife Partners Ii Lp sold 13,189 shares of the company’s stock in a transaction that occurred on Wednesday, December 27th. The stock was sold at an average price of $9.56, for a total transaction of $126,086.84. Following the completion of the transaction, the insider now directly owns 2,243,064 shares of the company’s stock, valued at $21,443,691.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Healthcare Master Fun Broadfin sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $10.00, for a total value of $1,000,000.00. The disclosure for this sale can be found here. Insiders have sold 860,414 shares of company stock valued at $8,289,916 over the last ninety days. Corporate insiders own 21.60% of the company’s stock.

Large investors have recently bought and sold shares of the company. Two Sigma Investments LP bought a new position in shares of Recro Pharma during the fourth quarter valued at approximately $164,000. JPMorgan Chase & Co. grew its holdings in shares of Recro Pharma by 183.4% during the third quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after purchasing an additional 14,098 shares during the last quarter. Strs Ohio grew its holdings in shares of Recro Pharma by 455.0% during the fourth quarter. Strs Ohio now owns 22,200 shares of the specialty pharmaceutical company’s stock valued at $205,000 after purchasing an additional 18,200 shares during the last quarter. Teachers Advisors LLC bought a new position in shares of Recro Pharma during the second quarter valued at approximately $162,000. Finally, California State Teachers Retirement System bought a new position in shares of Recro Pharma during the second quarter valued at approximately $169,000. 61.88% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Recro Pharma (REPH) Now Covered by Analysts at CIBC” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.chaffeybreeze.com/2018/02/15/recro-pharma-reph-now-covered-by-analysts-at-cibc.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply